View Cart  

Wingspan Stent’s Benefits Don’t Justify Risks, Panel Concludes

A A
Stryker’s Wingspan stent could be yanked from the market if the FDA heeds March 23 recommendations of its Neurological Devices Panel.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00